Trevena (TRVN) Competitors $0.25 0.00 (0.00%) As of 08/6/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. GLMD, ENVB, ELAB, LIPO, UBX, PRFX, CERO, PCSA, VCNX, and ADTXShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Galmed Pharmaceuticals (GLMD), Enveric Biosciences (ENVB), PMGC (ELAB), Lipella Pharmaceuticals (LIPO), UNITY Biotechnology (UBX), PainReform (PRFX), CERo Therapeutics (CERO), Heatwurx (PCSA), Vaccinex (VCNX), and Aditxt (ADTX). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors Galmed Pharmaceuticals Enveric Biosciences PMGC Lipella Pharmaceuticals UNITY Biotechnology PainReform CERo Therapeutics Heatwurx Vaccinex Aditxt Galmed Pharmaceuticals (NASDAQ:GLMD) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Is GLMD or TRVN more profitable? Trevena's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -32.21% -28.59% Trevena N/A N/A -119.55% Does the media refer more to GLMD or TRVN? In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Trevena. MarketBeat recorded 2 mentions for Galmed Pharmaceuticals and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 beat Galmed Pharmaceuticals' score of -0.81 indicating that Trevena is being referred to more favorably in the news media. Company Overall Sentiment Galmed Pharmaceuticals Negative Trevena Neutral Which has more volatility and risk, GLMD or TRVN? Galmed Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Do institutionals and insiders have more ownership in GLMD or TRVN? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, GLMD or TRVN? Galmed Pharmaceuticals has higher earnings, but lower revenue than Trevena. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.08Trevena$443K0.54-$40.29M-$47.04-0.01 Do analysts prefer GLMD or TRVN? Trevena has a consensus target price of $5.00, suggesting a potential upside of 1,900.00%. Given Trevena's higher probable upside, analysts clearly believe Trevena is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryGalmed Pharmaceuticals beats Trevena on 7 of the 12 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$240K$785.27M$5.48B$9.57BDividend YieldN/A4.84%3.99%4.17%P/E Ratio-0.011.2929.8925.14Price / Sales0.5425.43421.4486.79Price / CashN/A19.5635.9458.58Price / Book-0.026.578.125.59Net Income-$40.29M-$3.92M$3.26B$265.48M7 Day Performance-72.53%-2.83%0.69%1.22%1 Month Performance-72.53%-0.30%2.48%0.39%1 Year Performance-95.65%23.98%27.93%23.47% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena1.5364 of 5 stars$0.25flat$5.00+1,900.0%-95.3%$240K$443K-0.0140GLMDGalmed Pharmaceuticals0.6345 of 5 stars$1.91-4.0%N/A-59.9%$3.29MN/A-0.1120Short Interest ↑Gap DownENVBEnveric Biosciences2.3138 of 5 stars$1.26-3.8%$10.00+693.7%-87.0%$3.24MN/A-0.0320Upcoming EarningsELABPMGC0.2403 of 5 stars$2.27-0.4%N/A-99.6%$3.14M$1.71M-0.0118Positive NewsUpcoming EarningsShort Interest ↑LIPOLipella Pharmaceuticals1.3181 of 5 stars$0.69+10.2%N/A-86.8%$3.09M$536.36K-0.174Upcoming EarningsGap UpUBXUNITY Biotechnology4.0632 of 5 stars$0.18-40.4%$3.75+1,995.0%-87.3%$3.08MN/A-0.1160Gap DownHigh Trading VolumePRFXPainReform0.6378 of 5 stars$1.48-0.7%N/A+7.4%$3MN/A-0.014Positive NewsCEROCERo Therapeutics3.2939 of 5 stars$7.50-1.1%$45.00+500.0%-96.8%$2.93MN/A0.008News CoverageUpcoming EarningsPCSAHeatwurx2.1632 of 5 stars$0.23-4.7%$2.00+763.9%-87.1%$2.89MN/A-0.0820News CoveragePositive NewsEarnings ReportUpcoming EarningsGap DownVCNXVaccinexN/A$0.88+23.9%N/A-85.2%$2.76M$388K-0.0240Upcoming EarningsGap UpADTXAditxtN/A$1.22+2.5%N/A-100.0%$2.52M$130K0.0060Positive NewsGap Up Related Companies and Tools Related Companies GLMD Alternatives ENVB Alternatives ELAB Alternatives LIPO Alternatives UBX Alternatives PRFX Alternatives CERO Alternatives PCSA Alternatives VCNX Alternatives ADTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
